---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-007186"
form_type: "8-K"
ticker: null
cik: "0001267813"
company_name: "MARINUS PHARMACEUTICALS, INC."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T08:47:23.508934+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Marinus Q1 ZTALMY rev $7.5M (+125% YoY); cost cuts extend cash runway to Q1 2025; RAISE data summer

## Summary
- ZTALMY net product revenue $7.5M vs $3.3M YoY; full-year guidance raised to $33-35M from $32-34M.
- Phase 3 TrustTSC enrollment completes mid-May; topline data expected H1 Q4 2024; sNDA submission target April 2025.
- Phase 3 RAISE (IV ganaxolone in RSE) enrolled 100 patients; topline results early summer 2024; RAISE II stopped.
- Company reduced workforce ~20%, stopped RAISE/RAISE II enrollment, deferred IV ganaxolone manufacturing; cash $113.3M.
- Net loss $38.7M ($0.68/sh) vs $34.7M ($0.67/sh) in Q1 2023; total GAAP operating expenses guided $135-140M.

## SEC filing metadata
- accession: 0001558370-24-007186
- form_type: 8-K
- cik: 0001267813
- company_name: MARINUS PHARMACEUTICALS, INC.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267813/000155837024007186/0001558370-24-007186-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267813/000155837024007186/mrns-20240508x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-007186
- JSON: https://secwatch.observer/filing/0001558370-24-007186.json
- Plain text: https://secwatch.observer/filing/0001558370-24-007186.txt

## Key facts
- Earnings Releases
  MARINUS PHARMACEUTICALS, INC. reported first quarter ended March 31, 2024 results: revenue $7.5 million. Guidance raised.
  - Period: first quarter ended March 31, 2024
  - Revenue: $7.5 million
  - Guidance: raised
  - Result: reported results
  source text: (EX-99.1) --- ​ Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results ​ ● ZTALMY ® (ganaxolone) Q1 2024 net product revenue of $7.5 million representing strong growth of 125% versus Q1 2023 ● Increased full year 2024 projected U.S. ZTALMY net product revenues to between $33 and $35 million ● Enrollment to be
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267813/000155837024007186/0001558370-24-007186-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.